{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"18.4","value":"12.9"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"13.8","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the first documented complete response (CR: the disappearance of all target lesions and any pathological lymph nodes must have a short axis of \\<10 mm and the disappearance of all non-target lesions) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of ≥10mm) until disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5mm or the appearance of one or more new lesions, or the worsening of non target lesions significant enough to require study treatment discontinuation. PD was based on the radiological evidence by investigator. Only descriptive analysis performed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 milligram (mg) HPMC capsules orally twice daily (BID), once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib 2 mg once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib + Trametinib"},{"description":"Participants received dabrafenib 150 mg HPMC capsules orally BID, once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib placebo once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Crossover to the combination therapy arm was allowed for subjects still receiving study treatment on the dabrafenib monotherapy arm after the positive result for the final OS analysis.","id":"OG001","title":"Dabrafenib + Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population. Only those participants with a confirmed CR or PR were analyzed (with or without measurabe disease at Baseline).","reportingStatus":"POSTED","timeFrame":"From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}